WHITMORE R JANET 4

4 · SOLESENCE, INC. · Filed Dec 11, 2025

Form 4

Period: 2025-11-14

Director

Transactions

Holdings

Common Stock
2,049,142
Deferred Common Stock
→ Common Stock (20,030 underlying)
20,030
Common Stock (right to purchase)
Exercise: $1.85From: 2016-11-17Exp: 2026-11-17→ Common Stock (2,000 underlying)
2,000
Common Stock (right to purchase)
Exercise: $4.17From: 2022-12-28Exp: 2028-12-28→ Common Stock (20,000 underlying)
20,000
Common Stock (right to purchase)
Exercise: $1.17From: 2023-12-20Exp: 2029-12-20→ Common Stock (13,334 underlying)
13,334
Common Stock (right to purchase)
Exercise: $0.61From: 2024-12-27Exp: 2030-12-27→ Common Stock (12,600 underlying)
12,600
Common Stock (Right to Buy)
Exercise: $2.44From: 2025-12-31Exp: 2031-12-31→ Common Stock (12,000 underlying)
12,000

Footnotes (5)

[F1]Each share of deferred common stock represents the right to receive one share of common stock.
[F2]The deferred common stock becomes payable upon the reporting person's termination of service as a director of the Company.
[F3]Pursuant to such plan, the reporting person elected to defer receipt of such shares and receive a cumulative total of 20,030 shares of deferred common stock which will all be accounted for under the Company's Non-Employee Director Deferred Compensaion Plan.
[F4]The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. These 2000 shares were issued with an exercise price of $1.85.
[F5]Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.

Documents

1 file